Literature DB >> 31558624

Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial.

David Currow1,2, Sandra Louw3, Philip McCloud3, Belinda Fazekas4,2, John Plummer2, Christine F McDonald5,6, Meera Agar4, Katherine Clark7,8, Nikki McCaffrey2,9, Magnus Pär Ekström4,10.   

Abstract

INTRODUCTION: Morphine may decrease the intensity of chronic breathlessness but data from a large randomised controlled trial (RCT) are lacking. This first, large, parallel-group trial aimed to test the efficacy and safety of regular, low-dose, sustained-release (SR) morphine compared with placebo for chronic breathlessness.
METHODS: Multisite (14 inpatient and outpatient cardiorespiratory and palliative care services in Australia), parallel-arm, double-blind RCT. Adults with chronic breathlessness (modified Medical Research Council≥2) were randomised to 20 mg daily oral SR morphine and laxative (intervention) or placebo and placebo laxative (control) for 7 days. Both groups could take ≤6 doses of 2.5 mg, 'as needed', immediate-release morphine (≤15 mg/24 hours) as required by the ethics review board. The primary endpoint was change from baseline in intensity of breathlessness now (0-100 mm visual analogue scale; two times per day diary) between groups. Secondary endpoints included: worst, best and average breathlessness; unpleasantness of breathlessness now, fatigue; quality of life; function; and harms.
RESULTS: Analysed by intention-to-treat, 284 participants were randomised to morphine (n=145) or placebo (n=139). There was no difference between arms for the primary endpoint (mean difference -0.15 mm (95% CI -4.59 to 4.29; p=0.95)), nor secondary endpoints. The placebo group used more doses of oral morphine solution during the treatment period (mean 8.7 vs 5.8 doses; p=0.001). The morphine group had more constipation and nausea/vomiting. There were no cases of respiratory depression nor obtundation.
CONCLUSION: No differences were observed between arms for breathlessness, but the intervention arm used less rescue immediate-release morphine. TRIAL REGISTRATION NUMBER: ACTRN12609000806268. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chronic breathlessness; placebo study; randomised controlled trial; sustained release morphine; symptom relief

Year:  2019        PMID: 31558624     DOI: 10.1136/thoraxjnl-2019-213681

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  11 in total

Review 1.  Opioid Prescription Method for Breathlessness Due to Non-Cancer Chronic Respiratory Diseases: A Systematic Review.

Authors:  Yasuhiro Yamaguchi; K M Saif-Ur-Rahman; Motoko Nomura; Hiromitsu Ohta; Yoshihisa Hirakawa; Takashi Yamanaka; Satoshi Hirahara; Hisayuki Miura
Journal:  Int J Environ Res Public Health       Date:  2022-04-18       Impact factor: 4.614

2.  Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial.

Authors:  Cornelia A Verberkt; Marieke H J van den Beuken-van Everdingen; Jos M G A Schols; Niels Hameleers; Emiel F M Wouters; Daisy J A Janssen
Journal:  JAMA Intern Med       Date:  2020-10-01       Impact factor: 21.873

3.  Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial.

Authors:  Sissel Kronborg-White; Charlotte Uggerhøj Andersen; Charlotte Kohberg; Ole Hilberg; Elisabeth Bendstrup
Journal:  Respir Res       Date:  2020-07-23

Review 4.  Dyspnea in COPD: New Mechanistic Insights and Management Implications.

Authors:  Denis E O'Donnell; Kathryn M Milne; Matthew D James; Juan Pablo de Torres; J Alberto Neder
Journal:  Adv Ther       Date:  2019-10-30       Impact factor: 3.845

5.  A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease.

Authors:  Yet H Khor; Kirushallini Saravanan; Anne E Holland; Joanna Y T Lee; Christopher J Ryerson; Christine F McDonald; Nicole S L Goh
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.996

6.  Pharmacologic Interventions for Breathlessness in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

Authors:  Josephine L Feliciano; Julie M Waldfogel; Ritu Sharma; Allen Zhang; Arjun Gupta; Ramy Sedhom; Jeff Day; Eric B Bass; Sydney M Dy
Journal:  JAMA Netw Open       Date:  2021-02-01

7.  Research policy in supportive care and palliative care for cancer dyspnea.

Authors:  Yoshinobu Matsuda; Takashi Yamaguchi; Yoshihisa Matsumoto; Hiroto Ishiki; Yuko Usui; Jun Kako; Kozue Suzuki; Ryo Matsunuma; Masanori Mori; Hiroaki Watanabe; Sadamoto Zenda
Journal:  Jpn J Clin Oncol       Date:  2022-03-03       Impact factor: 3.019

8.  Predictors of Morphine Efficacy for Dyspnea in Inpatients with Chronic Obstructive Pulmonary Disease: A Secondary Analysis of JORTC-PAL 07.

Authors:  Yoshinobu Matsuda; Tatsuya Morita; Hirotaka Matsumoto; Keita Hosoi; Kayo Kusama; Yasuo Kohashi; Hiroshi Morishita; Sawako Kaku; Keisukie Ariyoshi; Shunsuke Oyamada; Yoshikazu Inoue; Satoru Iwase; Takuhiro Yamaguchi; Mitsunori Nishikawa
Journal:  Palliat Med Rep       Date:  2021-01-07

9.  Transmucosal Buprenorphine in the Treatment of Dyspnea: Case Series and Review of the Literature.

Authors:  François Blumenfeld-Kouchner; Lisa Bullis; Kathy Koch
Journal:  Palliat Med Rep       Date:  2021-01-12

Review 10.  Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD).

Authors:  Marlies van Dijk; Kris J M Mooren; Jan-Willem K van den Berg; Wendy J C van Beurden-Moeskops; Roxane Heller-Baan; Sander M de Hosson; Wai Yee Lam-Wong; Liesbeth Peters; Karin Pool; Huib A M Kerstjens
Journal:  BMC Pulm Med       Date:  2021-09-10       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.